The authors (1) presume the algorithm works and ask whether a risk assessment and the finding of a "nonischemic" electrocardiogram (ECG) helps the approach. It is not surprising these additions enhance the number of patients in the rule-out arm and improve the negative predictive value from 97.8% to 99.5% (3). They also improve sensitivity in the rule-in arm. Although the concept was confirmed, neither a defined risk score nor standardized ECG criteria were used, making extrapolation of these additions problematic.
Although the paper (1) is titled as if it is focused on ruling out adverse events, the focus is actually on ruling-in and ruling-out AMI as the primary goal.
From that perspective, the data have difficulties similar to other investigations that use this approach (3) . Given the importance of AMI, sufficient numbers of patients of all types must be assessed to ensure that there are no gaps. Some residual problems include: 2. Sex matters. The paucity of patients with AMI makes it unlikely there will be differences in sexassociated parameters. However, sex differences are apparent in studies with hs-cTn that included larger numbers of patients with AMI (7). The frequency of AMI in the study by Mokhtari et al. (1) was not high, and roughly 60% occurred in male subjects. Because nonobstructive coronary artery disease is more common in women, the likelihood of finding smaller MIs when one enrolls only modest numbers is remote (8). theheart.org), including the one that made the assay used in this study. One of the aspects reinforcing the potential clinical applicability of the study by Mokhtari et al. (1) is that the 30-day major adverse cardiac event rate was modest: only 0.5% in the rule-out group compared with 2.2% when the risk assessment and ECG components were not applied. Thus, these additions help.
P U B L I S H E D B Y E L S E V I E R h t t p :
However, how were these good outcomes achieved?
More than 50% of the population received additional cardiovascular evaluations and perhaps even more noncardiac evaluations. Employ defined risk stratification and ECG criteria.
Be of sufficient size to include large numbers of patients with AMI, including those who present early.
Enroll diverse populations, including more women.
Enroll "all comers" evaluated for AMI to refine the cutoff values necessary to optimize specificity. It is unlikely that any biomarker approach will ever allow these algorithms to have close-to-perfect specificity, but we should be able to get much closer.
Compare this approach versus a strategy using very low values to rule out AMI (4).
Evaluate the extent to which these approaches rely on follow-up investigations for their good results.
It should be clear that approaches should be capable of excluding AMI but not unstable angina. In addition, fulfilling criteria for "ruling-in" is not synonymous with AMI. We have started an important process, but at this point, the approaches suggested
are not yet "good enough."
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